Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 29-34

  Butts, Charles A ^a   Ding, Keyue ^a   Seymour, Lesley ^a   Twumasi Ankrah, Philip ^a   Graham, Barbara ^a   Gandara, David ^a   Johnson, David H ^a   Kesler, Kenneth A ^a   Green, Mark ^a   Vincent, Mark ^a   Cormier, Yvon ^a   Goss, Glenwood ^a   Findlay, Brian ^a   Johnston, Michael ^a   Tsao, Ming Sound ^a   Shepherd, Frances A ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CANCER STAGING; COMPARATIVE STUDY; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SECOND CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; VINBLASTINE;

EID: 73949154000     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.0333     Document Type: Article

References (23)

1. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997
2. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004
3. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005
4. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006
5. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552-3559, 2008
6. Fossa SD, Gilbert E, Dores GM, et al: Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99:533-544, 2007
7. Piccirillo JF, Tierney RM, Costas I, et al: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441-2447, 2004
8. Le Chevalier T, Dunant A, Arrigada R, et al: Long-term results of the International Adjuvant Lung Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell cancer (NSCLC). J Clin Oncol 26:398s, 2008 (suppl; abstr 7507)
9. Besse B, Le Chevalier T: Adjuvant chemotherapy for non-small-cell lung cancer: A fading effect? J Clin Oncol 26:5014-5017, 2008
10. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of the Cancer and Leukemia Group B (CALGB) Protocol 9633: J Clin Oncol 22:621s, 2004 (suppl; abstr 7019)
11. Strauss GM, Herndon JE, Maddaus MA, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043-5051, 2008
12. Clarke M, Coates AS, Darby SC, et al: Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: Patient-level meta-analysis of randomised trials. Lancet 371:29-40, 2008
13. Tammemagi CM, Neslund-Dundas C, Simoff M, et al: Smoking and lung cancer survival. Chest 125:27-37, 2004
14. Sardari Nia P, Weyler J, Colpaert C, et al: Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer 47:351-359, 2005
15. Tammemagi CM, Neslund-Dudas C, Simoff M, et al: Impact of comorbidity on lung cancer survival. Int J Cancer 103:792-802, 2003
16. Firat S, Bousamra M, Gore E, et al: Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:1047-1057, 2002
17. Strauss GM, Herndon JE, Maddaus MA, et al: Adjuvant chemotherapy in stage IB non-small-cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 24:365s, 2006 (abstr 7007)
18. Schiller JH, Adak S, Feins RH, et al: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 19:448-457, 2001
19. Scagliotti GV, Fossati R, Torri V, et al: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95:1453-1461, 2003
20. Keller SM, Vangel MG, Wagner H, et al: Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer 42:79-86, 2003
21. Kim DJ, Lee JG, Lee CY, et al: Long-term survival following pneumonectomy for non-small cell lung cancer: Clinical implications for follow-up care. Chest 132:178-184, 2007
22. Johnson BE: Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 90:1335-1345, 1998
23. Tucker MA, Murray N, Shaw EG, et al: Second primary cancers related to smoking and treatment of small-cell lung cancer. J Natl Cancer Inst 89:1782-1788, 1997